Segall Bryant & Hamill LLC raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 29.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 76,460 shares of the medical instruments supplier's stock after acquiring an additional 17,354 shares during the quarter. Segall Bryant & Hamill LLC owned 0.34% of LeMaitre Vascular worth $6,415,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new position in LeMaitre Vascular in the fourth quarter worth approximately $14,900,000. Rockefeller Capital Management L.P. acquired a new position in LeMaitre Vascular in the fourth quarter worth approximately $7,787,000. Invesco Ltd. increased its holdings in LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after buying an additional 58,720 shares during the last quarter. GAMMA Investing LLC increased its holdings in LeMaitre Vascular by 7,486.5% in the first quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock worth $4,519,000 after buying an additional 53,154 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in LeMaitre Vascular by 96.8% during the fourth quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier's stock valued at $8,853,000 after purchasing an additional 47,250 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.
LeMaitre Vascular Stock Performance
LMAT stock traded up $0.05 during midday trading on Monday, hitting $79.82. The stock had a trading volume of 102,976 shares, compared to its average volume of 168,922. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of 40.29, a P/E/G ratio of 2.10 and a beta of 0.82. The stock has a 50-day simple moving average of $82.82 and a 200 day simple moving average of $87.72. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a current ratio of 16.49, a quick ratio of 13.83 and a debt-to-equity ratio of 0.48.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The firm had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. During the same quarter in the previous year, the business earned $0.44 earnings per share. LeMaitre Vascular's revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.
LeMaitre Vascular Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 1.00%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's payout ratio is 40.40%.
Insider Buying and Selling
In related news, CEO George W. Lemaitre sold 4,399 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total transaction of $374,354.90. Following the transaction, the chief executive officer directly owned 1,827,003 shares of the company's stock, valued at approximately $155,477,955.30. The trade was a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 100,000 shares of company stock valued at $8,556,857. Insiders own 9.50% of the company's stock.
About LeMaitre Vascular
(
Free Report)
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Featured Articles
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
